Cyclacel Pharmaceuticals : March 2023 Corporate Presentation
June 13, 2023 at 07:49 am EDT
Share
Translating cancer biology into medicines
Presentation JUNE 2023
Disclaimer
This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward- looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling patients, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
STRATEGY: Leverage understanding of cancer biology to develop differentiated targeted oncology medicines with 1st or 2nd mover advantage to address unmet needs in women's cancers & lymphoma
SCIENCE: Leader in cell cycle checkpoint control and oncology drug innovator
ASSETS: Two Phase 1/2 ongoing studies for solid tumors and lymphoma
Fadraciclib - Oral CYC065, next generation CDK2/9 inhibitor
Single agent responses in unselected, late line solid tumors and lymphoma Plogosertib - Oral CYC140, PLK1 inhibitor with novel epigenetic MoA
Early indication of anticancer activity as a single agent
CATALYSTS: Three key 2023 data readouts from registration-directed Phase 1/2 studies
Cyclacel Pharmaceuticals Inc. published this content on 13 June 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 June 2023 11:48:08 UTC.
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
CYCLACEL PHARMACEUTICALS, INC. 
